CHA Biotech collaborates with VRI for NK cell therapy

[Courtesy of CHA Biotech]

CHA Biotech Co. will collaborate with its subsidiary, CHA Vaccine Research Institute (VRI), to develop an anticancer therapy aimed at enhancing the activity and anticancer effects of the natural killer (NK) cell treatment that is currently in development.

According to CHA Biotech on Thursday, the duo will cultivate NK cells and L-pampo, an immunostimulant developed by CHA VRI. The collaboration aims to analyze various active and inactive factors of NK cells and evaluate the anticancer efficacy to develop a new NK cell treatment.

L-pampo stimulates toll-like receptors (TLRs), the proteins in cells involved in innate immunity, by activating immune cells in the body and inducing an immune response. The two companies anticipate that L-pampo will interact with TLR2 and TLR3 expressed in NK cells, thereby increasing NK cells’ activity levels as well as enhancing anticancer effects.